Video

Clinical Implications of the IKEMA Trial in R/R MM

Author(s):

Brea Lipe, MD,Peter Forsberg, MD

Dr Forsberg details the safety data and toxicity management strategies of the IKEMA clinical trial.

Related Videos
1 expert in this video
1 expert in this video
2 KOLs are featured in this series.
Douglas W. Sborov, MD, MS
2 KOLs are featured in this series.
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Related Content
Syed Abbas Ali, MBBS
November 22nd 2024

Bispecific Antibodies and CAR T-Cell Therapies Continue to Reshape Myeloma Treatment Landscape

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

LASZLO – stock.adobe.com
November 14th 2024

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Extends OS in R/R Myeloma

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma
November 8th 2024

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma